Itraconazole does not affect the Pharmacokinetics of Micafungin (FK463)

N.A. Undre1, P. Stevenson1, A. Brooks2

Author address: 

1Astellas Pharma GmbH, Munich, Germany; 2Covance Clinical Research Unit, Leeds, UK


INTRODUCTION Micafungin (FK463) is an antifungal agent belonging to the echinocandin class used in patients who develop fungal infections. The metabolism of micafungin is mediated by CYP2A6 and CYP3A4 isozymes. In clinical practice, micafungin is likely to be used in combination with other drugs, and therefore knowledge of any potential pharmacokinetic interaction is necessary for safe concomitant use. Earlier studies have demonstrated a lack of interaction between micafungin and tacrolimus, cyclosporine, prednisolone, ritonavir and rifampicin. The current study was conducted to assess the potential for interaction between micafungin and itraconazole.

abstract No: 


Full conference title: 

17th European Congress of Clinical Microbiology and Infectious Diseases and 25th International Congress of Chemotherapy
    • ECCMID 17th (2007)